McCann L, Ozdogan H, Rutkowska-Sak L, Ferrandiz MA, Wulffraat NM, Brik R, . . . Lovell DJ. (2011). Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: Results from a phase III study. BMC.
Chicago Style (17th ed.) CitationMcCann L, et al. Efficacy and Safety of Canakinumab, a Long Acting Fully Human Anti-Interleukin-1β Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features: Results from a Phase III Study. BMC, 2011.
MLA (9th ed.) CitationMcCann L, et al. Efficacy and Safety of Canakinumab, a Long Acting Fully Human Anti-Interleukin-1β Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features: Results from a Phase III Study. BMC, 2011.